Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Diabetologia. 2013 Aug 10;56(11):10.1007/s00125-013-3009-7. doi: 10.1007/s00125-013-3009-7

Fig. 3.

Fig. 3

Effect of blockade of VMH B2AR receptors on the B2AR agonist response. GIR (a) and plasma concentrations of the counter-regulatory hormones adrenaline (b) and glucagon (c) in rats receiving microinjection of the artificial ECF vehicle (control; n=8), or the B2AR antagonist ICI-118,551 (n=8), during the hyperinsulinaemic–hypoglycaemic glucose clamp. The arrow indicates time when B2AR agonist was delivered. Circles and grey bars, B2AR agonist; squares and white bars, control. Results are presented as means ± SEM. *p<0.05 and ***p<0.001 vs control